Onco Actu du 1er avril 2015

Sommaire 1. Biologie Cancer Kismet [The Scientist] 2. Etiologie Genetics: Risk or destiny? [Mosaic] There’s a reason I use systematic reviews and meta-analyses [The Incidental Economist] 3. Prévention Resisting Cancer [The Scientist] 4. Dépistage, diagnostic et pronostic Sentinel lymph node mapping identifies positive lymph nodes in women with high-risk endometrial cancer, MD Anderson study finds [MD Anderson Cancer Center] My Mighty Mouse [The Scientist] 4.1 Dép., diag. & prono. - Prostate How GPs balance the dilemmas of prostate testing: study results [Croakey] 4.9 Dép., diag. & prono. - Sein Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer [ecancermedicalscience] 5. Traitements Knocking Out Melanoma: Does This Triple Combo Have What It Takes? [NIH Director's Blog] Bursting Cancer’s Bubble [The Scientist] The CAR T-Cell Race [The Scientist] 5.2 Pharma Pfizer is pharma’s biggest advertiser [Pharmafile] 5.2.1 Pharma - Partenariats Pivoting From IPO, Syndax Inks Combo Trial Deal With Merck [Xconomy] Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma [Merck] 5.3 Traitements - FDA, EMA,... EU Regulators Reveal 'Strategy to 2020' [RAPS] 5.4 Traitements - Economie New cancer drugs 'vastly overestimated', says contrarian analyst [Reuters] 5.6 ESMO Clinicians Hail Benefits of ESMO Clinical Practice Guidelines [ESMO] 6. Lutte contre les cancers Looking to the Future of Childhood Cancer Research [National Cancer Institute] Varmus Describes his Reasons for Leaving in Farewell Town Hall [The Cancer Letter] 6.5 Médecines alternatives Ancient cancer [Respectful Insolence] 6.6 Publications Cancer Cell issues big correction over "incorrectly cropped" figures, other issues [Retraction Watch] 6.7 DMP, Big Data & applis The Healing Power of Your Own Medical Records [NY Times] 6.8 Communication Thinking Ahead: From 'The Emperor Of All Maladies' To Precision Medicine In Cancer [Forbes] What I Hope Everyone Learns From PBS' Big Cancer Documentary [Forbes]

Les étoiles de couleur jaune signalent des articles dont la lecture est en priorité suggérée (1*) ou recommandée (3*). 1. Biologie Cancer Kismet [The Scientist] Fate mapping allows researchers to follow cancer progression from its cell type of origin. 2. Etiologie Genetics: Risk or destiny? [Mosaic] A visual approach to exploring the complex relationships between our health, genes, lifestyle and environment. There’s a reason I use systematic reviews and meta-analyses [The Incidental Economist] Of the 264 published studies, more than 70% found an association with a risk of cancer, some higher and some lower. When meta-analyses were published, though, the results (increased or decreased) were more conservative. That’s cause the outliers are more likely to get published. 3. Prévention Resisting Cancer [The Scientist] If one out of three people develops cancer, that means two others don’t. Understanding why could lead to insights relevant to prevention and treatment. 4. Dépistage, diagnostic et pronostic Sentinel lymph node mapping identifies positive lymph nodes in women with high-risk endometrial cancer, MD Anderson study finds [MD Anderson Cancer Center] The study offers promise the less-invasive procedure may one day serve as a staging tool for the most common gynecological malignancy -- as it does now for other cancers -- with fewer associated risks and complications to patients. My Mighty Mouse [The Scientist] Personal drug regimens based on xenograft mice harboring a single patient’s tumor still need to prove their true utility in medicine. 4.1 Dép., diag. & prono. - Prostate How GPs balance the dilemmas of prostate testing: study results [Croakey] For GPs on the frontline, decision-making about PSA testing is extremely difficult and complex. Understanding GPs’ reasoning in this way helps to explain why different GPs are making different testing decisions in similar cases. 4.9 Dép., diag. & prono. - Sein Highlights from the 14th St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer [ecancermedicalscience] The refinement of the classification, the risk of relapse and the prediction of response to multidisciplinary treatment for early breast cancer has been the major theme of the 14th St Gallen International Breast Cancer Consensus Conference 2015. 5. Traitements Knocking Out Melanoma: Does This Triple Combo Have What It Takes? [NIH Director's Blog] On average, the mice that received the triple-combination therapy (MEK inhibitor trametinib + BRAF inhibitor dabrafenib + immunotherapy, either anti-PD1 antibody or tumor antigen-specific adoptive cell transfer) lived at least twice as long as those that received the double-combination therapies. Bursting Cancer’s Bubble [The Scientist] Scientists make oxygen-filled microbubbles designed to increase tumor sensitivity to radiation. The CAR T-Cell Race [The Scientist] Tumor-targeting T-cell therapies are generating remarkable remissions in hard-to-beat cancers—and attracting millions of dollars of investment along the way. 5.2 Pharma Pfizer is pharma’s biggest advertiser [Pharmafile] The company spent $1.4 billion on advertising in the US last year, an increase of $261 million from 2013. 5.2.1 Pharma - Partenariats Pivoting From IPO, Syndax Inks Combo Trial Deal With Merck [Xconomy] A preclinical study published in the Proceedings of the National Academy of Sciences last year showed that entinostat might boost the effectiveness of two types of checkpoint drugs—PD-1 and CTLA-4 blockers, which help the immune system recognize tumors. Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA® (pembrolizumab) in Lung Cancer and Melanoma [Merck] The Phase 1b/2 study will evaluate this novel combination regimen in patients with either advanced non-small cell lung cancer (NSCLC) or melanoma. The study is expected to begin enrolling patients in the second half of 2015. 5.3 Traitements - FDA, EMA,... EU Regulators Reveal 'Strategy to 2020' [RAPS] European medicines regulators are asking for feedback on a newly released plan intended to lay out the European Medicines Agency (EMA) and the Heads of Medicines Agencies’ (HMA) strategic direction for the next five years. 5.4 Traitements - Economie New cancer drugs 'vastly overestimated', says contrarian analyst [Reuters] "We conclude that the global anti PD-1/PD-L1 market is worth an un-risk-adjusted $10 billion a year, materially less than the optimistic (in our view) $20-30 billion forecasts in the market today". 5.6 ESMO Clinicians Hail Benefits of ESMO Clinical Practice Guidelines [ESMO] Rectal cancer specialist Prof. Axel Grothey from the Mayo Clinic in Rochester, USA, said: “ ESMO Clinical Practice Guidelines on Rectal Cancer, and on other cancers, are popular internationally even outside Europe. This is because physicians in practice need guidance and ESMO’s guidelines are much more practice oriented than many other guidelines.” 6. Lutte contre les cancers Looking to the Future of Childhood Cancer Research [National Cancer Institute] Two overarching strategies to meet these challenges are precision medicine and immunotherapy. Varmus Describes his Reasons for Leaving in Farewell Town Hall [The Cancer Letter] In a farewell town hall meeting March 24, NCI Director Harold Varmus reflected on statements he made during his first day on the job, July 12, 2010, summarizing the proceeding four-and-three-quarter years; listing goals met and lamenting work left unfinished. 6.5 Médecines alternatives Ancient cancer [Respectful Insolence] If there’s one claim that irritates me that various proponents of alternative medicine like to make, it’s that cancer is a “modern” disease, that it was rare (or even didn’t exist) before the rise of modern societies, particularly the industrial revolution. 6.6 Publications Cancer Cell issues big correction over "incorrectly cropped" figures, other issues [Retraction Watch] The correction indicates that Western blots were cropped badly, which omitted several panels discussed in the text, while an “extra time point” was included accidentally. An antibody was also omitted from the description of the procedure. 6.7 DMP, Big Data & applis The Healing Power of Your Own Medical Records [NY Times] Some of the most advanced medical centers are starting to make medical information more available to patients. Brigham and Women’s, where Mr. Keating had his surgery, is part of the Partners HealthCare Group, which now has 500,000 patients with web access to some of the information in their health records including conditions, medications and test results. 6.8 Communication Thinking Ahead: From 'The Emperor Of All Maladies' To Precision Medicine In Cancer [Forbes] “The Emperor” chose neither a happy or sad ending to represent progress in pediatric cancer treatment. Rather, it engages the audience with one true story that leads to a good outcome and another that leads to death. The viewer can’t anticipate which child will live. What I Hope Everyone Learns From PBS' Big Cancer Documentary [Forbes] No surprise: PBS’ “Cancer: The Emperor of All Maladies” is exactly the documentary one wishes every person who has ever been captivated by a breathless news report about cancer research would watch first.